Structure Therapeutics Inc.
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small…
Biotechnology
US, South San Francisco [HQ]
GPCR/Financial Reporting
Income Statements
4 Sheets · Starting from 2020In Million USD. Margins, Growth Rates In %
| Metric | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Revenue | - - | - - | - - | - - | |
|
EPS
|
- - | - - | -1.40 | -2.44 | |
| Diluted in mil. | - - | - - | -1.40 | -2.44 | |
|
Profit
|
- - | - - | - - | - - | |
| Gross Margin | - - | - - | - - | - - | |
| Pre Tax | - - | - - | -51.00 | -89.00 | |
| Profit Margin | - - | - - | - - | - - | |
| ETR | -0.88 | -0.61 | -0.03 | -0.26 | |
| Net | - - | - - | -51.00 | -89.00 | |
| Profit Margin | - - | - - | - - | - - | |
| EBITDA | - - | - - | -52.00 | -101.00 | |
| EBITDA Margin | - - | - - | - - | - - | |
| Operating Income | - - | - - | -52.00 | -102.00 | |
| Operating Margin | - - | - - | - - | - - | |
| Interest Income | - - | - - | 1.00 | 13.00 | |
| Loss | - - | - - | -52.00 | -102.00 | |
| Cost of Revenue | - - | - - | - - | - - | |
|
Operating Expenses
|
- - | - - | -52.00 | -101.00 | |
| R&D | - - | - - | -36.00 | -70.00 | |
| G&A | - - | - - | -16.00 | -32.00 | |
| SG&A | - - | - - | -16.00 | -31.00 | |
| S&M | - - | - - | - - | - - | |
| Depreciation and Amortization | - - | - - | - - | - - | |
| Interest Expenses | - - | - - | -1.00 | -13.00 | |
| Other Expenses | - - | - - | -1.00 | -13.00 | |
|
WA Shares Outstanding
|
36.00 | 36.00 | 36.00 | 36.00 | |
| Diluted | 36.00 | 36.00 | 36.00 | 36.00 |